Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Huons Acquires Stake in PanGen to Bolster Biopharma Business | Contract Pharma
Breaking News

Huons Acquires Stake in PanGen to Bolster Biopharma Business

Plans to secure management rights and incorporate PanGen as a subsidiary.

Huons Co. Ltd. has announced a strategic investment of KRW 14.3 billion ($10.4 million) in PanGen Biotech Inc. to strengthen its biopharmaceutical R&D and CDMO capabilities.
 
The investment will see Huons acquire 2,647,378 shares of PanGen, giving it a 31.53% stake in the company. Following the acquisition, Huons plans to secure management rights and incorporate PanGen as a subsidiary.
 
PanGen brings to the table GMP facilities for biopharmaceutical production, as well as a proprietary cell line development technology known as “PanGen CHO-TECH.” This technology, coupled with PanGen’s productization capabilities, aligns well with Huons’ strategy to expand its biopharmaceutical offerings.
 
The two companies have already established a collaborative relationship. In June, PanGen signed a contract with Huonslab, a Huons subsidiary, to produce clinical samples of human hyaluronidase and conduct validation for product approval. Human hyaluronidase is a key ingredient in the development of subcutaneous formulations for various drugs, including cancer treatments and antibody therapies.
 
By acquiring a significant stake in PanGen, Huons aims to accelerate its entry into the biopharmaceutical CDMO business and solidify its position in the global healthcare market. The company believes that this strategic move will create significant synergies between its affiliates and drive future growth.

More Mergers & Acquisitions

Read Contract Pharma’s 2024 Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters